Home » Authors » Karen Young

Articles by Karen Young

Restoragen Cuts Half Its Staff, Plans To Rework Business Plan

Feb. 25, 2002

Cypress Enters Deal To Raise $17M, If Shareholders Approve

Feb. 22, 2002

Isis, Merck Form Collaboration Centered On Target Validation

Feb. 22, 2002

Isis, Merck Form Collaboration Centered On Target Validation

Feb. 22, 2002

Cypress Enters Deal To Raise $17M, If Shareholders Approve

Feb. 22, 2002

Albany Molecular, Bristol-Myers Rework Discovery Collaboration

Feb. 20, 2002

Albany Molecular Research Inc. signed a letter of intent with Bristol-Myers Squibb Co. to replace and consolidate Albany’s Molecular’s original agreement with DuPont Pharmaceuticals Co., in addition to signing a new agreement giving BMS access to AMRI’s natural products library. (BioWorld Today)

Albany Molecular, Bristol-Myers Rework Discovery Collaboration

Feb. 20, 2002

Albany Molecular Research Inc. signed a letter of intent with Bristol-Myers Squibb Co. to replace and consolidate Albany’s Molecular’s original agreement with DuPont Pharmaceuticals Co., in addition to signing a new agreement giving BMS access to AMRI’s natural products library. (BioWorld Today)

Repligen Begins Phase III Trials Of Secretin In Autistic Children

Feb. 19, 2002

Repligen Begins Phase III Trials Of Secretin In Autistic Children

Feb. 19, 2002

OmniScience, Ibis To Combine Technologies For Drug Discovery

Feb. 15, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.